[ad_1] Daclatasvir combined with sofosbuvir and ribavirin resulted in similar sustained virologic response rates in patients with genotype 2 and 3 hepatitis C compared to those treated with sofosbuvir and velpatasvir. This …
Read More »
[ad_1] World Day is the opportunity to raise awareness on this issue. The Villa Maraini Foundation, the National Agency for Drug Addiction of the Italian Red Cross, launches the "Evadere dalla C" …
Read More »
[ad_1] Italy, thanks to the treatment access policies introduced by IAAF, will achieve WHO's goal of reducing by 65% the mortality correlated with HCV in 2022 and, according to the latest badyzes …
Read More »
[ad_1] The clbadification of viral genotypes of hepatitis C expands. To date, we know 7 genotypes based on the structure of which have been perfected direct-acting antiviral drugs that nowadays allow the …
Read More »